A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib

Summary

This is a single arm, multi-center study to evaluate the efficacy and safety of orelabrutinib for Chronic lymphocytic lymphoma（CLL)/small lymphocytic lymphoma (SLL) patients who are slowly responding to Ibrutinib switched to Orelabrutinib.

Timeline

Start

2022-01-01

Primary completion

2024-08-28

Completion

2024-08-30

Drugs

Indications